1. Pink Sheet

First Academic Sponsor On EMA’s PRIME Pledges Cheaper CAR-Ts

 
• By Neena Brizmohun

An investigational CAR T-cell therapy that hospital researchers in Spain believe they could produce at a third of the price of commercially available CART19 products has been accepted onto the European Medicines Agency's priority medicines scheme.

A new CAR-T therapy is being developed to treat leukemia • Source: Alamy

ARI-0001, an investigational CAR T-cell therapy for leukemia, has become the first product by a developer from the academic sector to make it onto PRIME, the European Medicines Agency’s priority medicines scheme.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography